Therapy News and Research

RSS

TCT for Surgeons to showcase hybrid surgical, interventional techniques during TCT 2010

TCT for Surgeons will showcase the expansion of hybrid surgical and interventional techniques in the field that are improving outcomes for patients undergoing cardiac surgery. Now in its 4th year, the course will run during Transcatheter Cardiovascular Therapeutics 2010 (September 21-25), the annual scientific symposium of the Cardiovascular Research Foundation.

5 May 2010

Azithromycin does not improve lung function in children with cystic fibrosis

Children and adolescents with cystic fibrosis who received the antibiotic azithromycin did not experience improved lung function, compared to patients who received placebo, according to a study in the May 5 issue of JAMA.

5 May 2010

Data shows rates of colorectal cancer screening vary by race, ethnicity and method

Rates of colorectal cancer screening vary by race and ethnicity as well as method, according to data being presented at Digestive Disease Week- 2010. Scientists examine data on minority and older populations as well as utilization rates of virtual and optical colonoscopies to better understand adherence to recommended screening guidelines.

5 May 2010

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1). Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%.

5 May 2010

Study: Parvovirus therapy offers complete regression of malignant brain tumors

Particular parvoviruses normally infect rodents, but they are also infectious for human cells. However, they do not cause any disease symptoms in humans. Most importantly, these viruses have an astonishing property: They kill infected tumors cells without causing any damage to healthy tissue.

5 May 2010

Deloitte Survey: Consumers still profess to know very little about health care system in the U.S.

Following widespread media coverage of health care reform, political debates and legislative initiatives over the past year, consumers still profess to know very little about the health care system in the United States, according to the 3rd Annual Deloitte Center for Health Solutions Survey of Health Care Consumers.

5 May 2010

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Anavex Life Sciences Corp. is pleased to report promising results from animal studies with ANAVEX 2-73, the company's lead compound for the treatment and modification of Alzheimer's disease.

5 May 2010

Calgary doctors research how to minimize complications from Cryptococcus disease

Cryptococcus disease is a rare but serious infection resulting from inhaling a toxic fungus often found in fir trees. Approximately 250 people have been infected with the disease in British Columbia since its emergence in 1999. The disease can cause meningitis, pneumonia and in 10 per cent of cases it can lead to death.

5 May 2010

Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010

Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented this afternoon as an oral communication at a late breaking forum of the American Gastroenterological Association Institute during Digestive Disease Week 2010 in New Orleans, Louisiana.

5 May 2010

Additional pivotal Phase 3 trial data for MoxDuo IR released

QRxPharma announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy. Required for New Drug Application submission with the United States Food and Drug Administration, this "combination rule" study compared the efficacy and safety profiles of MoxDuo IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery.

5 May 2010

Myriad Genetics' third-quarter fiscal 2010 revenues increase 5% to $90.8M

Myriad Genetics, Inc. today reported financial results for the third fiscal quarter and the nine-month period ended March 31, 2010.

5 May 2010

Adjuvant chemotherapy after gastric cancer procedure may reduce mortality

Patients who have gastric cancer surgery followed by chemotherapy have an associated decreased risk of death and improved disease-free survival compared to patients who have surgery alone, according to an analysis of previous studies, reported in the May 5 issue of JAMA.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Second fidaxomicin Phase 3 clinical study data in patients with CDI to be presented at DDW 2010

Optimer Pharmaceuticals, Inc. announced the presentation of new data from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection. The data, presented by Stuart Johnson, M.D. during an oral session at the annual meeting of Digestive Disease Week in New Orleans, indicated that treatment with fidaxomicin significantly improved the recurrence rate and global cure rate in CDI patients requiring concomitant antibiotics, compared to vancomycin.

5 May 2010

Roche announces Health Canada approval for ACTEMRA to treat RA

Roche today announced that Health Canada has approved ACTEMRA(TM) (tocilizumab) to treat patients with rheumatoid arthritis (RA), a chronic, progressive inflammatory disease of the joints and surrounding tissues that is associated with intense pain, irreversible joint destruction and systemic complications, such as fatigue and anemia.

4 May 2010

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.

4 May 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.

4 May 2010

Early treatment of ROP for high-risk premature babies can improve vision: ETROP study

Scientists have shown that through eye examinations, doctors can identify infants who are most likely to benefit from early treatment for a potentially blinding eye condition called retinopathy of prematurity, resulting in better vision for many children.

4 May 2010

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

GTx, Inc. today reported financial results for the first quarter of 2010. The net income for the first quarter ended March 31, 2010 was $44.3 million compared with a net loss of $11.3 million for the same period in 2009. Net income for the current period included the recognition of approximately $54.9 million in collaboration revenue due to the termination of our license and collaboration agreement with Merck & Co., Inc in March 2010.

4 May 2010

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.

4 May 2010

Therapy News and Research

TCT for Surgeons to showcase hybrid surgical, interventional techniques during TCT 2010

Azithromycin does not improve lung function in children with cystic fibrosis

Data shows rates of colorectal cancer screening vary by race, ethnicity and method

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

Study: Parvovirus therapy offers complete regression of malignant brain tumors

Deloitte Survey: Consumers still profess to know very little about health care system in the U.S.

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Calgary doctors research how to minimize complications from Cryptococcus disease

Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010

Additional pivotal Phase 3 trial data for MoxDuo IR released

Myriad Genetics' third-quarter fiscal 2010 revenues increase 5% to $90.8M

Adjuvant chemotherapy after gastric cancer procedure may reduce mortality

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Second fidaxomicin Phase 3 clinical study data in patients with CDI to be presented at DDW 2010

Roche announces Health Canada approval for ACTEMRA to treat RA

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Early treatment of ROP for high-risk premature babies can improve vision: ETROP study

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News